Chinese
GenScript ProBio is the bio-pharmaceutical CDMO segment of the world's leading biotech company GenScript Biotech Corporation (Stock Code: 1548.HK). Founded in 2002 in New Jersey, GenScript started business from gene synthesis. Now, GenScript ProBio’s businesses encompass four major categories based on its leading gene synthesis technology, including operation as a Life Science CRO, enzyme and synthetic biology products, biologics development and manufacturing, as well as cell therapy.
In Jan 2019, GenScript established the Biologics Development Business Unit (BDBU) which is the predecessor of GenScript ProBio.
The name of "ProBio" indicates 3 core philosophies - being PROACTIVE, PROFESSIONAL and PROCESS-oriented. GenScript ProBio shows our dedication to proactively provide end to end service (discovery to commercialization) with professional solutions, and efficient process to accelerate drug development for customers.
GenScript ProBio has established the integrated innovative biologics CDMO platforms, covering two major service areas: therapeutic antibody drug and gene & cell therapy. We are committed to driving innovation and accelerating biologics development from target to market.
GenScript ProBio's one-stop antibody drug development solutions include antibody drug discovery (hybridoma, phage display, single B cell, fully human and bispecific antibody technologies), antibody engineering (antibody humanization, affinity maturation, developability assessment and optimization), antibody development (stable cell line generation, process development), and clinical and commercial manufacturing. GenScript ProBio's integrated GCT solution covers IND preparation as well as clinical sample and commercial production. Process development quality systems ensure compliance, data integrity and traceability, and all test deviations are strictly studied and documented. With the principle of "providing the best-in-class quality to and serving the interests of customers", GenScript ProBio is committed to helping customers to shorten the timeline for biological drugs from development to clinical use, significantly cutting down the R&D costs, accelerating the commercialization of medicines, and building a healthy future while making contributions to the development of the pharmaceutical industry.